Published online Jul 14, 2022. doi: 10.3748/wjg.v28.i26.3092
Peer-review started: January 16, 2022
First decision: April 11, 2022
Revised: April 21, 2022
Accepted: June 19, 2022
Article in press: June 19, 2022
Published online: July 14, 2022
Processing time: 177 Days and 7.7 Hours
The rapid progress of research into inflammatory bowel disease (IBD) has resulted in increasingly more treatment options. Different options have different advantages and disadvantages, and the preferences of patients may also differ. If patients can be invited to the formulation of medical decision-making, their compliance and satisfaction would be improved, thus possibly achieving better therapeutic results. The present review aims to summarize the current literature on shared decision-making (SDM) in the management of IBD, with the goal of promoting the application of SDM.
Core Tip: It is often challenging to make therapeutic decisions for patients with inflammatory bowel disease (IBD), given the uncertainty of therapeutic options and diverse patient values. Shared decision-making (SDM) is a process to formulate treatment with patients, trying to clarify and take account of the preferences of patients, increasing their compliance and satisfaction. We summarize current evidence and illustrate the necessity of applying SDM in IBD management.